ANG Lifesciences India Board of Directors
Get the latest insights into the leadership at ANG Lifesciences India. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Rajesh Gupta | Managing Director |
| Mrs. Saruchi Gupta | Whole Time Director |
| Mr. Rohit Mittal | Non Executive Director |
| Mr. Sukhpal Singh | Independent Director |
| Mr. Harvinder Singh | Independent Director |
| Mrs. Chetna | Independent Director |
ANG Lifesciences India Share price
ANG
35.28
0.63 (-1.75%)Last updated on 25 Sep, 2025 | 15:47 IST
BUYSELL
Today's High
36.80
Today's Low
34.50
52 Week Low
21.03
52 Week High
55.95
The current prices are delayed, login to your account for live prices
LoginANG Lifesciences India FAQs
The board at ANG Lifesciences India consists of experienced professionals, including Mr. Rajesh Gupta , Mrs. Saruchi Gupta , and others, overseeing the company’s strategic and corporate governance.
Directors at ANG Lifesciences India are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Rajesh Gupta is the current chairman at ANG Lifesciences India.
Executive directors at ANG Lifesciences India are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, ANG Lifesciences India adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At ANG Lifesciences India, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.